Richard Lowenthal resigns from ARS Pharmaceuticals board

Richard Lowenthal resigned from the board of directors of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on July 15, 2026, effective immediately.

According to a company statement, Lowenthal's resignation was a condition of his right to receive severance compensation under the terms of his employment agreement and the company's Change in Control and Severance Benefit Plan. The arrangement was previously described in the company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 29, 2026.

Also on July 15, 2026, Sarina Tanimoto, M.D., the company's Chief Medical Officer, ceased employment with ARS Pharmaceuticals under conditions constituting a termination without cause.

You May Also Be Interested In

• DBV Technologies refreshes ATM program with $150M ADS offering
• ACI Worldwide exploring sale of billing division - Reuters
• Trump: I asked Darline Graham to run for U.S. senate in special Republican primary on Tuesday, August 11